Larazotide acetate is the only peptide ever designed to directly block zonulin, the protein that opens tight junctions and increases intestinal permeability. In Phase 2b trials, larazotide at 0.5 mg significantly reduced celiac disease symptoms in patients already following a gluten-free diet (Leffler et al., Gastroenterology 2015). Then the Phase 3 CedLara trial was discontinued in 2022 after an interim analysis showed the sample size needed for statistical significance was unfeasibly large. The failure was about trial design and endpoints, not safety. Here is what the data actually showed, what went wrong, and what it means for anyone interested in targeting leaky gut at the tight junction level.
What Is Larazotide Acetate?
Larazotide acetate (originally designated AT-1001) is a synthetic octapeptide, a chain of eight amino acids, designed to block zonulin from opening tight junctions in the intestinal lining. It is the first and only drug ever developed to directly target the zonulin pathway.
The compound traces back to Alessio Fasano's landmark discovery of zonulin in 2000 at the University of Maryland. Fasano identified zonulin as the endogenous human analog of Vibrio cholerae's zonula occludens toxin (Zot), a bacterial protein that causes the watery diarrhea of cholera by prying open tight junctions. Larazotide was modeled on a fragment of Zot that competitively blocks zonulin's receptor.
Development passed through several hands. Alba Therapeutics brought larazotide through early clinical trials. Innovate Biopharmaceuticals acquired the program and merged with 9 Meters Biopharma, which sponsored the Phase 3 trial. As of 2026, 9 Meters has no active larazotide program for celiac disease.
Three properties define larazotide:
- Local action. It works in the gut lumen with minimal systemic absorption. This gave it an excellent safety profile across all trial phases.
- First-in-class. No other pharmaceutical agent directly targets zonulin. Every other gut permeability intervention works downstream or through indirect mechanisms.
- Celiac-specific development. It was designed for celiac disease patients who remain symptomatic despite a gluten-free diet, a population that represents 30-50% of diagnosed celiacs.
The Zonulin-Leaky Gut-Autoimmune Connection
Zonulin is an endogenous protein that regulates the permeability of tight junctions between intestinal epithelial cells. Fasano first characterized it in 2000, and his subsequent work built the case that increased intestinal permeability is not merely a consequence of autoimmune disease but a prerequisite for its development.
The pathway works like this. Gliadin (the prolamin fraction of gluten) binds to the CXCR3 receptor on enterocytes, triggering zonulin release. Zonulin then binds to receptors on the basolateral surface of intestinal cells, initiating a signaling cascade that disassembles tight junction protein complexes. The result is increased paracellular permeability: gaps open between cells, and dietary antigens, bacterial products, and other luminal contents cross into the lamina propria where immune cells reside.
In genetically susceptible individuals, this antigen translocation activates immune responses that can progress to full autoimmune disease. Fasano's "leaky gut hypothesis" (formalized in multiple publications from 2011 to 2020) proposes three requirements for autoimmune disease: genetic predisposition, an environmental trigger, and increased intestinal permeability. Remove any one, and the disease process stalls.
Elevated zonulin levels have been documented in celiac disease, type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, and multiple sclerosis. This is what made larazotide so conceptually important. If you could block zonulin, you might be able to prevent the permeability increase that precedes immune activation. It was the first direct pharmacological test of Fasano's hypothesis.
For more on how gluten and intestinal permeability drive joint inflammation through zonulin and molecular mimicry pathways, see our deep-dive on that connection.
How Larazotide Restores Tight Junctions
Larazotide functions as a competitive zonulin receptor antagonist. It occupies the receptor binding site on enterocytes, preventing zonulin from initiating its downstream signaling cascade.
The specific mechanism involves four steps, as characterized in the pharmacological review by Sauri-Sos and Rodriguez-Lagunas (AJP-GI Liver Physiol 2021):
- Receptor blockade. Larazotide binds to the zonulin receptor on enterocyte surfaces, preventing zonulin attachment.
- Signaling prevention. Without receptor activation, the intracellular signaling cascade that normally leads to tight junction disassembly does not fire.
- Tight junction protein stabilization. ZO-1, occludin, and claudin proteins remain properly localized at junctional complexes rather than being redistributed away from cell-cell contact points.
- Cytoskeletal preservation. The actin cytoskeleton maintains its organization. Normally, zonulin signaling causes actin rearrangement that physically pulls tight junctions apart. Larazotide prevents this contraction.
The local action of larazotide is a significant advantage. Because it acts in the gut lumen and is minimally absorbed systemically, it avoids the off-target effects that systemic drugs carry. This translated to an excellent safety profile: across all clinical trial phases, larazotide showed no significant adverse events compared to placebo.
Recent research has expanded the understood scope of larazotide's protective effects. A 2025 study in Biomedicines demonstrated that larazotide protects intestinal cells against anoxia/reoxygenation injury, a model relevant to ischemia-reperfusion damage in the gut. This suggests the compound may have barrier-protective properties beyond pure zonulin blockade.
Clinical Trial History
Phase 1 (2005-2007): Safety Confirmed
The initial safety studies established that larazotide was well tolerated at multiple doses. Systemic absorption was minimal. No significant adverse events were reported. These results cleared the path for efficacy testing.
Phase 2a (2009): Proof of Concept
The Phase 2a trial provided the first human evidence that larazotide could modulate intestinal permeability. In celiac patients exposed to a controlled gluten challenge, larazotide reduced both intestinal permeability and gastrointestinal symptoms compared to placebo. The study was small but directionally clear.
Phase 2b (Leffler et al. 2015): The Positive Signal
This was the pivotal study that justified Phase 3. Published in Gastroenterology, Leffler et al. enrolled 342 celiac disease patients who were already following a gluten-free diet but still had persistent symptoms, a common clinical reality.
Three doses were tested: 0.25 mg, 0.5 mg, and 1 mg, all taken three times daily. The 0.5 mg dose significantly reduced symptoms compared to placebo, as measured by the Celiac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS). The 0.25 mg and 1 mg doses did not reach significance, suggesting a narrow therapeutic window.
The results earned larazotide FDA Fast Track designation. The evidence grade for this indication is Grade B: a single well-designed RCT showing significant symptom reduction in a relevant patient population.
Key findings from Phase 2b:
- Symptom improvement was significant at 0.5 mg but not at other doses
- Safety profile remained clean with no significant adverse events vs. placebo
- The benefit was seen in patients already on a gluten-free diet, meaning larazotide addressed residual permeability that dietary restriction alone could not eliminate
- The effect was modest in absolute terms, which would become relevant in Phase 3
Phase 3 CedLara Trial (2019-2022): Discontinued
The CedLara trial, sponsored by 9 Meters Biopharma, enrolled 525 patients across three arms: two larazotide doses and placebo. It was designed as a 24-week study. In June 2022, an independent statistician conducted a pre-planned interim analysis and determined that the sample size needed to detect a statistically significant difference between larazotide and placebo would be unfeasibly large.
The trial was discontinued. This was not a safety failure. No safety signals emerged in the interim data. The problem was statistical power.
Why the Phase 3 trial likely failed:
High placebo response. GI trials are notoriously susceptible to placebo effects. Patients who believe they are receiving treatment for gut symptoms often report improvement regardless of what they receive. The placebo response rate in CedLara appears to have been higher than anticipated from Phase 2b data, narrowing the detectable treatment effect.
Patient selection paradox. The trial enrolled celiac patients who were adherent to a gluten-free diet. These patients may have had relatively low zonulin-driven permeability to begin with. The very patients most likely to benefit from zonulin blockade (those with poor dietary adherence or high residual gluten exposure) were excluded by the inclusion criteria.
Endpoint sensitivity. The CeD-GSRS measures subjective gastrointestinal symptoms. Larazotide's primary action is on tight junction permeability, a biochemical change that does not necessarily map directly to symptom scores. A permeability-focused endpoint (lactulose/mannitol ratio, serum zonulin levels, or mucosal biopsy findings) might have captured larazotide's actual effect more accurately.
Dose optimization questions. The Phase 2b dose-response curve was unusual. Only the middle dose (0.5 mg) worked. This inverted U-shape pattern can complicate Phase 3 design and suggests the therapeutic window may be narrow.
What the Phase 3 Failure Actually Means
The discontinuation of CedLara created a narrative vacuum that most health sites filled poorly. Many still carry outdated "Phase 3 pending" content. Others simply state "the trial failed" without context. Neither framing is accurate.
Larazotide did not fail because zonulin modulation does not work. The zonulin-permeability-autoimmunity hypothesis (Fasano) remains scientifically sound and well-supported by independent research. What failed was the ability of this specific trial design to demonstrate a large enough clinical effect to reach statistical significance.
Larazotide validated something important: you can target tight junctions pharmacologically. The compound reached its biological target. The challenge is that the gap between reducing intestinal permeability (a biochemical measurement) and improving patient-reported symptoms (a subjective clinical outcome) is larger than anticipated.
One piece of evidence that keeps the zonulin-targeting concept alive comes from outside celiac disease entirely. Tajik et al. (Nature Communications 2020) demonstrated that larazotide prevented the onset of arthritis in genetically predisposed mice by blocking zonulin-mediated intestinal permeability. The study showed that increased gut permeability preceded joint inflammation, and that larazotide administered before disease onset could prevent it. This is direct experimental support for Fasano's hypothesis that permeability is a prerequisite, not just a consequence.
The implications for the broader "leaky gut" concept are nuanced:
- Mechanistic validation. Zonulin-driven permeability is real and targetable. Larazotide proved this in humans.
- Clinical translation gap. Reducing permeability does not automatically produce measurable symptom improvement, at least not with current measurement tools.
- Future potential. Better trial designs, different endpoints, or different patient populations might reveal the clinical benefit that Phase 3 could not detect.
For general leaky gut applications outside celiac disease, larazotide carries an evidence grade of Grade C: mechanistic and preclinical evidence without clinical trial confirmation.
Current Status and Access (2026)
As of March 2026, larazotide acetate occupies a peculiar position: scientifically validated but commercially abandoned for its original indication.
Pharmaceutical status. Larazotide is not FDA-approved for any condition. 9 Meters Biopharma has no active larazotide clinical program for celiac disease. The company redirected its resources toward vurolenatide (NM-003) and other pipeline compounds. Additional subgroup analyses from CedLara data may still be published, but no new celiac trials are planned.
MIS-C investigation. One active area of research is a Phase 2 trial studying larazotide for multisystem inflammatory syndrome in children (MIS-C), a post-COVID condition characterized by elevated zonulin levels and gut barrier dysfunction. This trial reflects the logical extension of larazotide's mechanism to conditions where zonulin-driven permeability is clearly elevated.
Compounding access. Some compounding pharmacies offer research-grade larazotide acetate. Combined oral capsule formulations containing BPC-157, KPV, and larazotide are available from peptide suppliers. These products are not FDA-regulated, and quality control varies between suppliers. Anyone considering compounded peptides should discuss this with their physician and understand the regulatory and quality limitations.
Future prospects. The concept of pharmacological tight junction modulation is not dead. Academic groups continue to study zonulin-targeting approaches, and a better-designed trial (with biomarker-driven endpoints, better patient selection, or combination approaches) could revisit larazotide or a next-generation zonulin antagonist. The mechanism remains one of the most promising targets in gut barrier research.
Alternatives for Targeting Intestinal Permeability
While larazotide remains the only compound designed to directly block zonulin, several alternatives target intestinal permeability through different mechanisms. These range from well-studied supplements with human trial data to research compounds with preclinical evidence only.
L-glutamine is the most evidence-backed option for reducing intestinal permeability. It is the primary fuel source for enterocytes and supports tight junction protein expression. Human clinical data supports its use for gut barrier function, and it is inexpensive, widely available, and safe at standard doses. For dosing protocols, see our L-glutamine for leaky gut guide.
Zinc carnosine provides mucosal protection and has been shown to reduce NSAID-induced intestinal permeability in a human RCT (Mahmood et al. 2007). It chelates to damaged mucosa and promotes healing. Typical dose is 75 mg twice daily.
BPC-157 is a gastric pentadecapeptide with extensive animal evidence for mucosal healing, cytoprotection, and tissue repair. It operates through VEGF upregulation, NO system modulation, and growth factor activation. No human trials have been completed. It is a Tier 3 option after foundational supplements are in place. See our full BPC-157 for gut healing evidence review.
Colostrum contains immunoglobulins and growth factors that reduce intestinal permeability. Playford et al. (2001) showed it prevented NSAID-induced gut permeability increases in humans. It is well-tolerated and commercially available.
Butyrate is a short-chain fatty acid produced by gut bacteria during fiber fermentation. It enhances barrier function by upregulating tight junction proteins and serving as the primary energy source for colonocytes. Supplemental sodium butyrate or tributyrin can be used when dietary fiber intake is insufficient.
Dietary approaches address the trigger side rather than the mechanism side. Eliminating gluten removes the primary zonulin trigger. The autoimmune protocol (AIP) diet eliminates multiple potential permeability triggers simultaneously. These approaches are foundational and should be in place before considering any peptide intervention.
For a broader comparison of peptides for autoimmune disease, including how larazotide fits alongside BPC-157, KPV, TB-500, and thymosin alpha-1, see our peptide hub.
Frequently Asked Questions
What happened to the larazotide clinical trial for celiac disease?
The Phase 3 CedLara trial was discontinued in June 2022 after an independent interim analysis determined the required sample size for statistical significance was unfeasibly large. This was not a safety failure. The treatment effect was too small relative to the placebo response to reach significance with the planned enrollment of 525 patients. No new celiac disease trials are currently planned by 9 Meters Biopharma.
Can larazotide fix leaky gut?
Larazotide blocks zonulin from opening tight junctions, which reduces intestinal permeability in controlled settings. Phase 2 data confirmed this mechanism works in humans with celiac disease. Whether it can address generalized "leaky gut" in non-celiac autoimmune conditions has not been tested in clinical trials. The mechanism is sound, but clinical evidence is limited to celiac disease. For general leaky gut support, L-glutamine and zinc carnosine have more applicable human evidence.
Is larazotide the same as BPC-157?
No. They are fundamentally different compounds with different mechanisms. Larazotide is an octapeptide (8 amino acids) that blocks zonulin receptors to prevent tight junction opening. BPC-157 is a pentadecapeptide (15 amino acids) derived from gastric juice that promotes mucosal healing through angiogenesis, VEGF upregulation, and growth factor modulation. Larazotide prevents barrier breakdown. BPC-157 repairs barrier damage. They address different stages of gut dysfunction and are sometimes combined in compounded formulations.
Is larazotide safe?
Across all clinical trial phases (Phase 1 through Phase 3 interim), larazotide showed no significant adverse events compared to placebo. Its local mechanism of action (minimal systemic absorption from the gut lumen) gives it an inherently favorable safety profile. The Phase 3 trial was not discontinued due to safety concerns. Long-term safety data beyond 24 weeks does not exist, and compounding pharmacy formulations have not undergone the same quality controls as clinical trial material.
Who discovered zonulin and why does it matter?
Alessio Fasano at the University of Maryland (now at Massachusetts General Hospital/Harvard) identified zonulin in 2000 as the human analog of Vibrio cholerae's zonula occludens toxin. His subsequent research established the "leaky gut hypothesis": that increased intestinal permeability is a prerequisite (not just a consequence) of autoimmune disease development. This framework connects celiac disease, type 1 diabetes, IBD, RA, and other autoimmune conditions through a shared gut barrier mechanism. Larazotide was the first direct pharmacological test of this hypothesis.
Are there alternatives to larazotide for reducing intestinal permeability?
Yes. L-glutamine has the strongest human evidence for supporting gut barrier function. Zinc carnosine reduces NSAID-induced permeability (Mahmood 2007 RCT). BPC-157 has extensive animal evidence for mucosal healing. Colostrum prevents permeability increases (Playford 2001). Butyrate supports tight junction protein expression. Dietary interventions (gluten elimination, AIP diet) address triggers directly. None of these block zonulin specifically, but they support barrier integrity through complementary mechanisms. A layered approach starting with diet and foundational supplements before considering peptides is the most evidence-based strategy.
This article is for educational purposes only and does not constitute medical advice. Larazotide acetate is not FDA-approved and is not commercially available as a pharmaceutical. Celiac disease requires strict adherence to a gluten-free diet regardless of any adjunct therapy. Compounding pharmacy peptides are not FDA-regulated. Discuss any gut permeability treatment with your gastroenterologist before use.
Not sure which gut healing interventions match your condition and severity? Take the free 3-minute AutoimmuneFinder quiz to get your personalized protocol.